Zephex® 152a

Zephex® 152a is a new, sustainable medical propellant that has been under development by Koura for several years for use in metered dose inhalers (MDIs) for treatment of respiratory disorders such as asthma and COPD.

This new medical propellant has been under development for several years for use in metered-dose inhalers (MDIs) for treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). Zephex® 152a reduces the carbon footprint of an MDI, helping to safeguard an invaluable therapeutic option for patients.

Key Benefits

Reduces the carbon
footprint of MDIs by 90%

Low GWP

Global Warming Potential (GWP) is a measure of the atmospheric warming potential of a propellant upon release into the atmosphere. Pressurised metered-dose-inhalers using Zephex® 152a will bring about a greater than 90% reduction in GWP compared to some current MDI propellants¹.

As a result, the use of Zephex® 152a will result in an environmental impact comparable to other ‘green’ technologies, including dry powder inhalers, when accounting for manufacturing, use and disposal. Utilization of the 152a molecule as a lower GWP inhaler propellant addresses concerns of both patients and pharmaceutical companies².

1. Inhalation Mag (December 2017) – Reducing carbon footprints in metered dose inhalers

2. Transitioning to low-GWP alternatives in aerosols